Agios Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 138% revenue growth to $20.7M, driven by a strong AQVESME launch in thalassemia and robust U.S. demand. Mitapivat sNDA for sickle cell disease is on track for Q2, and the pipeline remains catalyst-rich with key data readouts expected this year.
-
Mitapivat’s launch in thalassemia is off to a strong start, with expansion into sickle cell disease and other indications underway. Regulatory updates and key data readouts are expected throughout the year, while commercial focus remains on the U.S. market and broadening patient access.
-
A major growth phase is underway, driven by the U.S. launch of Aqvesme for thalassemia and expansion of the PK activator franchise into new indications. The pipeline targets over $10 billion in global market potential by 2030, with disciplined financial management and key clinical milestones expected in 2024.
Fiscal Year 2025
-
Q4 and full-year 2025 saw robust PYRUKYND revenue growth and the successful US launch of ACTIVASE for thalassemia, with strong early demand and physician engagement. The company ended 2025 with $1.2B in cash and expects continued growth and key pipeline catalysts in 2026.
-
Mitapivat (Aqneusa) received FDA approval as the first oral therapy for anemia in adults with alpha or beta thalassemia, supported by robust phase 3 data. Launch is set for late January, with a REMS program and initial focus on transfusion-dependent patients.
-
The phase III RISE UP trial showed mitapivat significantly improved hemoglobin in 40.6% of sickle cell disease patients, with robust reductions in pain crises and hospitalizations among responders, and a favorable safety profile. The company plans to seek FDA approval following a pre-SNDA meeting in 2026.
-
Q3 2025 net revenue grew 44% year-over-year to $12.9 million, driven by PYRUKYND's commercial momentum and global regulatory progress. Strong cash reserves support upcoming U.S. launches and pipeline advancement, with key data readouts and regulatory milestones expected by year end.
-
Q2 2025 net revenue grew 45% year-over-year to $12.5M, driven by PYRUKYND, with U.S. Thalassemia launch pending FDA approval and ex-U.S. expansion progressing via partnerships. Cash reserves remain strong at $1.3B, supporting continued pipeline and commercial investment.
-
Two major catalysts are expected: Pyrukynd's PDUFA for thalassemia in September and RISE UP phase III data for sickle cell disease by year-end, with global expansion via partnerships. The pipeline includes next-generation PK activators and new assets, supported by a strong balance sheet and disciplined business development.
-
The conference highlighted strong progress in rare blood disorder therapies, with pivotal thalassemia studies supporting regulatory filings and a key FDA decision expected in September. Commercial and clinical teams are prepared for launches, while the pipeline advances with new PK activators.
-
PYRUKYND is advancing toward broad thalassemia approval with a September 2025 PDUFA date, while commercialization plans prioritize the U.S. and strategic partnerships abroad. Sickle cell phase III data are expected by year-end, and a strong cash position supports pipeline expansion and disciplined growth.
-
Q1 2025 saw 6% year-over-year revenue growth for Pyrukynd, with strong progress toward a potential thalassemia launch in September and a pivotal sickle cell disease readout by year-end. The company maintains a robust $1.4B cash position and disciplined capital allocation.
-
PYRUKYND is advancing toward broader indications, with thalassemia and sickle cell pivotal trials progressing and regulatory filings underway in multiple regions. Commercial infrastructure is expanding, and a strong cash position supports pipeline growth and potential back-to-back launches.
-
Significant progress was made in rare blood disorder therapies, with key regulatory filings for thalassemia and sickle cell, and robust clinical data supporting patient benefit. Commercial expansion is focused on the U.S., Gulf, and Europe, with strong financial resources backing future launches.
-
Key milestones include positive phase III thalassemia data, regulatory filings, and a PDUFA date for September 2024. Sickle cell disease trials advance with promising efficacy and safety, while commercial and R&D teams prepare for multiple launches. New leadership strengthens business development.
-
The conference highlighted robust progress in rare disease therapeutics, with PYRUKYND poised for major launches in thalassemia and sickle cell disease, a diversified pipeline advancing, and a strong financial position enabling disciplined growth and business development.
Fiscal Year 2024
-
Q4 2024 saw strong revenue growth for Pyrukynd and major pipeline progress, including positive pediatric PK deficiency data and regulatory filings in thalassemia. The company is well-funded, expects flat PK deficiency revenues in 2025, and is preparing for key launches and clinical milestones.
-
Q3 2024 saw strong financial results, with $1.7B in cash and $9M in Pyrukynd revenue, driven by milestone payments and positive clinical progress in rare blood disorders. Mitapivat is on track for thalassemia and sickle cell launches, with robust commercial and R&D execution.
-
Leadership outlined a robust rare disease strategy, highlighting mitapivat's strong clinical data in PK deficiency, thalassemia, and sickle cell disease. Regulatory filings and global expansion are on track, with a solid financial position supporting future launches.
-
Q2 2024 saw strong clinical and commercial progress, highlighted by positive phase 3 data for mitapivat in thalassemia and pediatric PK deficiency, a major royalty monetization deal, and robust cash reserves. Preparations for US and GCC launches are underway, with regulatory submissions and key data readouts expected in 2024–2025.
-
Mitapivat demonstrated significant efficacy and safety in phase 3 thalassemia studies, with broad improvements in hemoglobin, fatigue, and function. Regulatory filings are planned globally, and the therapy is expected to address major unmet needs for both alpha and beta thalassemia.
-
Mitapivat demonstrated robust efficacy in thalassemia and sickle cell disease, with pivotal trials supporting broad label inclusion and durable patient benefits. Commercial and global launch preparations are underway, backed by a strong balance sheet and expanding pipeline.